SEC Filing · S-8
Precision BioSciences, Inc.
DTILNASDAQEQUITYCurrent
SEC Filing
Company context
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of
Current securities
Recent company filings
- Regulation FD Disclosure · Other EventsAug 24, 2026
- 10-Q filingAug 6, 2026
- Results of Operations and Financial ConditionAug 6, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureJul 27, 2026
- SCHEDULE 13G filingJul 20, 2026
As-filed source
As filedOpen full document ↗